Know Cancer

forgot password

A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE on Myeloma Related Bone Disease

Phase 2
18 Years
Open (Enrolling)
Multiple Myeloma

Thank you

Trial Information

A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE on Myeloma Related Bone Disease

This is a randomized, open-label (all people involved know the identity of the
intervention), multicenter, multi-country parallel group study (each group of patients will
be treated at the same time) in patients with Multiple Myeloma (MMY) who have received high
dose chemotherapy and autologous stem cell transplantation for primary treatment of MMY
(single- or double-transplant). The purpose of the study is to assess the effect of
bortezomib on myeloma-related bone disease by analyzing bone mineral density. Approximately
80% of patients with MMY may experience myeloma-related bone disease. Myeloma-related bone
disease may cause skeletal complications, including bone pain, bone lesions, abnormal
fractures and super-elevated calcium concentrations in the blood. This study is
investigating the safety and efficacy of an experimental drug, bortezomib, to consolidate
the response to the primary treatment compared to no such consolidation treatment. The
analyses in this study will be exploratory in nature, since the study will not address any
pre-defined statements but is designed to generate valid hypotheses on safety and efficacy
issues. Bortezomib is currently marketed for the treatment of different types of cancer
including MMY. Bortezomib has been shown to promote bone formation and increase the number
of bone-regenerating cells in preliminary studies. In the present study, the effect of
bortezomib on bone formation will be assessed by dual energy x-ray absorptiometry (DXA)
measuring bone mineral density, which is a measure for the quality of the bone structures.
Several bone markers will be measured on serum samples. Bone markers are indicators of the
bone activity. Patients will be evaluated for eligibility within a 14-day screening period,
after providing written informed consent. Eligible patients will then be randomised to
either bortezomib or observation alone. Baseline efficacy and safety assessments should be
available on Cycle 1 Day 1 prior to administration of study medication. Randomization will
be stratified by bisphosphonate treatment (use or not) at baseline and age (65 years or more
versus less than 65 years). The treatment period is defined as the time the patient is
actively receiving study treatment. Patients in the bortezomib arm will receive treatment of
bortezomib for a total of 4 cycles or until start of alternative MMY treatment if earlier.
Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive
bortezomib 1.6 mg/m2 on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period
(Days 23 to 35). Bisphosphonate therapy can be administered as medically indicated and
according to local practice. Patients are to attend study center visits on Days 1, 8, 15,
and 22 of each treatment cycle or at Days 1, 36, 71, and 106 in the observation arm and at
end of treatment (EOT) Visit. During these visits, different evaluations will be conducted
to follow treatment safety: symptom directed physical examination, vital signs and
laboratory tests. In addition, at Day 1 of Cycle 3 (prior to dosing) or Day 71 in the
observation arm, patients will be assessed for disease progression or relapse by
measurements of M-protein in serum and urine. If needed, absence of M-protein in serum and
urine will be confirmed by immunofixation. Additional evaluations may be performed to
document patient's clinical status and ability to tolerate additional therapy as clinically
indicated. All patients will be followed for a total of 24 months since baseline. After end
of the treatment phase, there will be a long-term follow-up period with visits at 4, 6, 12
and 18 months after the EOT Visit. In case the patient started alternative MMY treatment
before completing the 18 months of follow-up, study assessments will stop, except for QoL
assessments, which are to be continued up to 18 months of follow-up, and for a long-term
follow-up for survival, which will be collected every 6 months by either a telephone call or
a visit to the study site. The follow-up for survival will continue for all patients until
the last patient has completed follow-up. In addition to scheduled visits, patients may have
additional visits as clinically indicated. Every patient who was randomized should enter the
long-term follow-up phase. Assessment of progressive disease (PD) or relapse from complete
response (CR) should be performed according to the International Myeloma Working Group
(IMWG) 2009 criteria. Changes in serum and urine M-protein (monoclonal paraprotein) levels
will be confirmed by immunofixation in patients without measurable serum and urine M-protein
levels. Karnofsky performance status will also be assessed. Safety will be assessed by
monitoring of adverse events, physical examination (including neurological/peripheral
neurological examinations), vital signs measurements and clinical laboratory tests. A total
of two exploratory analyses will be performed for the present study: The first analysis
(main analysis) will be presented after completion of the EOT Visit (24-weeks data). The
second analysis will be the analysis at the end of the study on 18 months follow-up data.
Patients in the bortezomib arm will receive treatment of bortezomib 1.6 mg/m² as a bolus
infusion on Days 1, 8, 15, and 22 every 5 weeks for a total of 4 cycles

Inclusion Criteria:

- Adult Multiple Myeloma patients in partial response or better after high dose
chemotherapy and autologous stem cell transplantation

- Patient fulfills defined laboratory requirements within 14 days before enrolment

- If female, is either postmenopausal for more than 24 consecutive months or surgically
sterilized or willing to use an acceptable method of birth control for defined period

- If male, agree to use an acceptable barrier method of contraception and to not donate
sperm up to 3 months following treatment

Exclusion Criteria:

- Patient received another antimyeloma or experimental therapy following autologous
stem cell transplantation

- Patient has a peripheral neuropathy or neuropathic pain of grade 2 or greater
intensity as defined by the NCI common terminology criteria of adverse event (NCI
CTCAE) version 3.0

- Patient has an uncontrolled or severe cardiovascular disease within 6 months of

- Patient has any conditions that would compromise his/her well-being or the completion
of the study requirements

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Change from baseline in bone mineral density (BMD) at end of Treatment

Outcome Description:

Change from baseline in bone mineral density (BMD) will be assessed by dual energy x-ray absorptiometry scans at baseline and the end of treatment EOT visit

Outcome Time Frame:

at screening (i.e. between 14 and 1 days prior to start of treatment) and at end of treatment (EOT), i.e. 24 weeks after randomization or until start of alternative MMY therapy, if earlier

Safety Issue:


Principal Investigator

Janssen-Cilag International NV Clinical Trial

Investigator Role:

Study Director

Investigator Affiliation:

Janssen-Cilag International NV


Belgium: Ministry of Social Affairs, Public Health and the Environment

Study ID:




Start Date:

September 2009

Completion Date:

April 2014

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • bortezomib
  • hematology
  • bone marrow cancer
  • Myeloma-related bone disease
  • bone mineral density
  • bone markers
  • Bone Diseases
  • Multiple Myeloma
  • Neoplasms, Plasma Cell